Impact of specific mutations on PARP inhibition in prostate cancer

preview_player
Показать описание
Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He dicusses a recent publication by his group on the impact of certain genes mutations on PARP inhibition in prostate cancer, including ATM, CDK12 and BRCA1/2.
Рекомендации по теме